Non-frequent AEs (occurring in only one participant in any treatment arm) that were rated probably or possibly related to the trial product included dizziness, somnolence, diarrhea and upper abdominal pain in the somapacitan group, and limb discomfort, pain in extremity, face edema, fat tissue decreased, diabetes, and subcutaneous hemorrhage in the daily GH group, as well as a case of back pain in both groups. Here, GH1 is linked to diabetes mellitus.